StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

AnaptysBio's operating income for the twelve months ending Jun 30, 2026 was $312.93M, up 229.5% year over year. For fiscal 2025 it was $226.90M, up 243.0% from the year before. The highest annual figure on record is $226.90M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$226.90M+243.0%
FY2024Dec 31, 2024$66.15M–
FY2023Dec 31, 2023-$164.41M–
FY2022Dec 31, 2022-$115.15M–
FY2021Dec 31, 2021-$56.81M–
FY2020Dec 31, 2020-$23.88M–
FY2019Dec 31, 2019-$107.43M–
FY2018Dec 31, 2018-$66.72M–
FY2017Dec 31, 2017-$28.78M–
FY2016Dec 31, 2016-$3.03M–
FY2015Dec 31, 2015-$3.32M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$66.96M–
Q1 FY2026Mar 31, 2026-$34.64M–
Q4 FY2025Dec 31, 2025$245.91M+43.4%
Q3 FY2025Sep 30, 2025$34.70M–
Q2 FY2025Jun 30, 2025-$26.17M–
Q1 FY2025Mar 31, 2025-$27.54M–
Q4 FY2024Dec 31, 2024$171.43M–
Q3 FY2024Sep 30, 2024-$22.76M–
Q2 FY2024Jun 30, 2024-$40.32M–
Q1 FY2024Mar 31, 2024-$42.20M–
Q4 FY2023Dec 31, 2023-$42.14M–
Q3 FY2023Sep 30, 2023-$37.73M–
Q2 FY2023Jun 30, 2023-$40.14M–
Q1 FY2023Mar 31, 2023-$44.40M–
Q4 FY2022Dec 31, 2022-$25.97M–
Q3 FY2022Sep 30, 2022-$29.63M–
Q2 FY2022Jun 30, 2022-$27.80M–
Q1 FY2022Mar 31, 2022-$31.75M–
Q4 FY2021Dec 31, 2021-$31.16M-193.4%
Q3 FY2021Sep 30, 2021-$6.76M–
Q2 FY2021Jun 30, 2021-$533.00K–
Q1 FY2021Mar 31, 2021-$18.36M–
Q4 FY2020Dec 31, 2020$33.35M–
Q3 FY2020Sep 30, 2020-$24.34M–
Q2 FY2020Jun 30, 2020-$22.64M–
Q1 FY2020Mar 31, 2020-$10.25M–
Q4 FY2019Dec 31, 2019-$22.26M–
Q3 FY2019Sep 30, 2019-$33.75M–
Q2 FY2019Jun 30, 2019-$26.66M–
Q1 FY2019Mar 31, 2019-$24.77M–
Q4 FY2018Dec 31, 2018-$19.66M–
Q3 FY2018Sep 30, 2018-$16.89M–
Q2 FY2018Jun 30, 2018-$14.42M–
Q1 FY2018Mar 31, 2018-$15.76M–
Q4 FY2017Dec 31, 2017-$7.15M–
Q3 FY2017Sep 30, 2017-$9.09M–
Q2 FY2017Jun 30, 2017-$2.56M–
Q1 FY2017Mar 31, 2017-$9.99M–
Q4 FY2016Dec 31, 2016-$3.17M–
Q3 FY2016Sep 30, 2016-$1.08M–

More AnaptysBio figures

See a number that looks wrong?